CA2637253A1 - Anticorps anti-troponine et risque cardiovasculaire - Google Patents

Anticorps anti-troponine et risque cardiovasculaire Download PDF

Info

Publication number
CA2637253A1
CA2637253A1 CA002637253A CA2637253A CA2637253A1 CA 2637253 A1 CA2637253 A1 CA 2637253A1 CA 002637253 A CA002637253 A CA 002637253A CA 2637253 A CA2637253 A CA 2637253A CA 2637253 A1 CA2637253 A1 CA 2637253A1
Authority
CA
Canada
Prior art keywords
antibodies
risk
troponin
cardiac troponin
marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002637253A
Other languages
English (en)
Inventor
Klaus Hallermayer
Hugo Katus
Ziya Kaya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F. Hoffmann-La Roche Ag
Klaus Hallermayer
Hugo Katus
Ziya Kaya
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/340,012 external-priority patent/US20070172888A1/en
Application filed by F. Hoffmann-La Roche Ag, Klaus Hallermayer, Hugo Katus, Ziya Kaya filed Critical F. Hoffmann-La Roche Ag
Publication of CA2637253A1 publication Critical patent/CA2637253A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA002637253A 2006-01-25 2007-01-23 Anticorps anti-troponine et risque cardiovasculaire Abandoned CA2637253A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP06001483.4 2006-01-25
EP06001483 2006-01-25
US11/340,012 2006-01-25
US11/340,012 US20070172888A1 (en) 2006-01-25 2006-01-25 Measuring troponin antibodies to assess cardiovascular risk
PCT/EP2007/000537 WO2007085411A1 (fr) 2006-01-25 2007-01-23 Anticorps anti-troponine et risque cardiovasculaire

Publications (1)

Publication Number Publication Date
CA2637253A1 true CA2637253A1 (fr) 2007-08-02

Family

ID=37749974

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002637253A Abandoned CA2637253A1 (fr) 2006-01-25 2007-01-23 Anticorps anti-troponine et risque cardiovasculaire

Country Status (4)

Country Link
EP (1) EP1979748A1 (fr)
JP (1) JP2009524807A (fr)
CA (1) CA2637253A1 (fr)
WO (1) WO2007085411A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776605B2 (en) 2006-10-26 2010-08-17 Abbott Laboratories Assay for cardiac troponin autoantibodies
JP5057402B2 (ja) 2006-10-26 2012-10-24 アボット・ラボラトリーズ 内在性の抗分析物抗体を含有する試料中の分析物の免疫アッセイ
WO2008080030A2 (fr) * 2006-12-22 2008-07-03 Abbott Laboratories Panel de maladies auto-immunes cardiovasculaires et méthodes d'utilisation correspondantes
EP2427767A4 (fr) * 2009-05-05 2013-01-23 Yeda Res & Dev Moyens et méthodes pour reconnaître le développement d'une maladie cardiovasculaire chez un individu
JP5675829B2 (ja) 2009-10-15 2015-02-25 クレッシェンド バイオサイエンス インコーポレイテッド 炎症性疾患活動性を測定およびモニタリングするためのバイオマーカーおよび方法
JP2011206049A (ja) 2010-03-08 2011-10-20 Sumio Sugano 壊死マーカー及びその用途
JP5683253B2 (ja) * 2010-12-21 2015-03-11 晃生 佐野 未病判定方法
CN105980857B (zh) * 2013-11-15 2018-07-13 奥塔哥创新有限公司 用于心脏病症的生物标记物
WO2015153437A1 (fr) 2014-04-02 2015-10-08 Crescendo Bioscience Biomarqueurs et procédés de mesure et de surveillance de l'activité de l'arthrite idiopathique juvénile
JP2017523437A (ja) 2014-06-10 2017-08-17 クレッシェンド バイオサイエンス インコーポレイテッド 体軸性脊椎関節炎の疾患活動性を測定およびモニタリングするためのバイオマーカーおよび方法
US20180246121A1 (en) * 2015-08-21 2018-08-30 Fuso Pharmaceutical Industries, Ltd. Immunological test method and immunological test kit
WO2017058999A2 (fr) 2015-09-29 2017-04-06 Crescendo Bioscience Biomarqueurs et méthodes d'évaluation de la réponse à l'arrêt d'une thérapie contre les maladies inflammatoires
CA3207751A1 (fr) 2015-09-29 2017-04-06 Laboratory Corporation Of America Holdings Biomarqueurs et procedes d'evaluation de l'activite de la maladie arthrite psoriasique
WO2018079393A1 (fr) 2016-10-26 2018-05-03 扶桑薬品工業株式会社 Anticorps spécifique de hmgb1 de type disulfure, procédé de mesure de hmgb1 de type disulfure et kit pour ladite mesure, ainsi qu'un procédé de mesure capable de quantifier toutes les molécules de hmgb1 comprenant une hmgb1 réduite, une hmgb1 de type disulfure et une hmgb1 pouvant être clivée par la thrombine et kit pour ladite mesure

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03004105A (es) * 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.

Also Published As

Publication number Publication date
WO2007085411A1 (fr) 2007-08-02
JP2009524807A (ja) 2009-07-02
EP1979748A1 (fr) 2008-10-15

Similar Documents

Publication Publication Date Title
US20070172888A1 (en) Measuring troponin antibodies to assess cardiovascular risk
CA2637253A1 (fr) Anticorps anti-troponine et risque cardiovasculaire
JP4343866B2 (ja) 容量過負荷の結果として心血管合併症に罹患するリスクを評価するための心臓ホルモンの使用
JP6654668B2 (ja) 発作性心房細動のｂｎｐ型ペプチドに基づく診断をするためのデータを提供する方法
US20060286681A1 (en) Proximal markers of arterial thrombosis and inflammation for risk stratification of coronary heart disease
ES2305541T3 (es) Scd40l, papp-a y factor de crecimiento placentario (pigf) como combinaciones de marcadores bioquimicos en enfermedades cardiovasculares.
CA2585271C (fr) Plgf et sflt-1 en tant que parametres pronostiques dans le cadre de troubles cardio-vasculaires
US8062896B2 (en) Cardiac hormones for assessing cardiovascular risk
KR101678703B1 (ko) 갈렉틴-３ 면역검정
US20060166303A1 (en) Use of cardiac hormones for assessing a cardiovascular risk with respect to the administration of anti-inflammatory drugs
JP4870686B2 (ja) 抗炎症剤の投与に関連する心血管リスクを評価するための心臓ホルモンの使用
ES2390359T3 (es) Troponina cardiaca como marcador de enfermedad arterial coronaria avanzada
CA2610910A1 (fr) Procedes et compositions du diagnostic de maladie thrombo-embolitique veineuse
EP2279419A1 (fr) Facteur gdf-15 utilisé comme biomarqueur dans le diabète de type 1
JP7058331B2 (ja) 脳卒中の予測のための循環アンジオポエチン－２（Ａｎｇ－２）およびインスリン様増殖因子結合タンパク質７（ＩＧＦＢＰ７）
CN101371144A (zh) 抗肌钙蛋白抗体和心血管风险
EP2103943A1 (fr) GDF-15 pour évaluer un risque cardiovasculaire en respectant l'administration des médicaments anti-inflammatoires
EP2133696A1 (fr) Concentrations très faibles de troponine I ou T pour évaluer un risque cardiovasculaire en fonction de l'administration de médicaments anti-inflammatoires
EP1691200A1 (fr) L'utilisation des peptides de type BNP et ANP pour évaluer les risques des complications cardiovasculaires dues a une surcharge de volume
WO2012146723A1 (fr) Sflt-1 et troponine t en tant que biomarqueurs d'embolie pulmonaire

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued